CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications - Results of a retrospective analysis of 117 cases

Clinical Rheumatology

Volumn 25, Issue 4, 2006, Pages 482-486

  Kötter, Ina ^a   Günaydin, Ilhan ^a   Batra, Marion ^a   Vonthein, Reinhard ^a   Stübiger, Nicole ^a   Fierlbeck, Gerhard ^a   Melms, Arthur ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Beh et's disease; CNS manifestations; CSA

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CYCLOSPORIN A; METHOTREXATE; PREDNISONE; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; BEHCET DISEASE; BRAIN VASCULITIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG PULSE THERAPY; EYE DISEASE; FEMALE; FISHER EXACT TEST; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUROLOGIC DISEASE; PREVALENCE; PRIORITY JOURNAL; SKIN DEFECT; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AUTONOMIC NERVOUS SYSTEM DISEASES; AZATHIOPRINE; BEHCET SYNDROME; COHORT STUDIES; COMORBIDITY; CYCLOSPORINE; DISEASE PROGRESSION; EYE DISEASES; FEMALE; GERMANY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INTERFERON-ALPHA; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 33746549075     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-005-0070-8     Document Type: Article

References (23)

1. International Study Group for Behcet's Disease (1990) Criteria for diagnosis of Behcet's disease. Lancet 335:1078-1080
2. Kidd D, Steuer A, Denman AM, Rudge P (1999) Neurological complications in Behcet's syndrome. Brain 122(Pt 11):2183-2194
3. Akman-Demir G, Serdaroglu P, Tasci B (1999) Clinical patterns of neurological involvement in Behcet's disease: Evaluation of 200 patients. The Neuro-Behcet Study Group. Brain 122(Pt 11):2171-2182
4. Siva A, Kantarci OH, Saip S, et al (2001) Behcet's disease: Diagnostic and prognostic aspects of neurological involvement. J Neurol 248:95-103
5. Dilsen N, Konice M, Aral O (1985) Our diagnostic criteria of Behcet's disease - an overview. In: Lehner T, Barnes CG (eds) Recent advances in Behçet's disease. Royal Society of Medicine Services, London, pp 177-180
6. Krause I, Rosen Y, Kaplan I, et al (1999) Recurrent aphthous stomatitis in Behcet's disease: Clinical features and correlation with systemic disease expression and severity. J Oral Pathol Med 28:193-196
7. Kotter I, Vonthein R, Muller CA, Gunaydin I, Zierhut M, Stubiger N (2004) Behcet's disease in patients of German and Turkish origin living in Germany: A comparative analysis. J Rheumatol 31:133-139
8. Saenz A, Ausejo M, Shea B, Wells G, Welch V, Tugwell P (2000) Pharmacotherapy for Behcet's syndrome. Cochrane Database Syst Rev 2:CD001084
9. Hinchey J, Chaves C, Appignani B, et al (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334:494-500
10. Gijtenbeek JMM, van den Bent MJ, Vecht CJ (1999) Cyclosporine neurotoxicity: A review. J Neurol 246:339-346
11. Filley CM, Kleinschmidt-DeMasters BK (2001) Toxic leukoencephalopathy. N Engl J Med 345:425-432
12. Lee SH, Yoon PH, Park SJ, Kim DI (2001) MRI findings in neuro-Behçet's disease. Clin Radiol 56:485-494
13. Kato Y, Numaga J, Kato S, Kaburaki T, Kawashima H, Fujino Y (2001) Central nervous system symptoms in a population of Behcet's disease patients with refractory uveitis treated with cyclosporine A. Clin Experiment Ophthalmol 29:335-336
14. Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H (1999) Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology 106:586-589
15. Meusser S, Eger G, Anders M, Burkhardt H, Kalden JR (1997) Manifestation of neuro-Behcet disease in cyclosporin A therapy. Z Rheumatol 56:31-39
16. Lannuzel A, Lamaury I, Charpentier D, Caparros-Lefebvre D (2002) Neurological manifestations of Behcet's disease in a Caribbean population: Clinical and imaging findings. J Neurol 249:410-418
17. Serdaroglu P (1998) Behcet's disease and the nervous system. J Neurol 245:197-205
18. McLean BN, Miller D, Thompson EJ (1995) Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behcet's disease involving the nervous system. J Neurol Neurosurg Psychiatry 58:548-554
19. Motomura S, Tabira T, Kuroiwa Y (1980) A clinical comparative study of multiple sclerosis and neuro-Behcet's syndrome. J Neurol Neurosurg Psychiatry 43:210-213
20. Krause I, Leibovici L, Guedj D, Molad Y, Uziel Y, Weinberger A (1999) Disease patterns of patients with Behcet's disease demonstrated by factor analysis. Clin Exp Rheumatol 17:347-350
21. Yurdakul S, Mat C, Tuzun Y, et al (2001) A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 44:2686-2692
22. Hamuryudan V, Mat C, Saip S, et al (1998) Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:443-450
23. Kotter I, Vonthein R, Zierhut M, et al (2004) Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: Results of an open 4-center trial. Semin Arthritis Rheum 33:311-319